Tazemetostat

The FDA granted accelerated approval to tazemetostat for the treatment of adults with relapsed or refractory follicular lymphoma.

The FDA granted accelerated approval to tazemetostat for patients aged 16 years or older with metastatic or locally advanced epithelioid sarcoma ineligible for complete resection.

In this video, Joshua Brody, MD, director of the lymphoma immunotherapy program at Tisch Cancer Institute at Mount Sinai, discusses major unmet needs in the treatment of follicular lymphoma, including challenges treating early relapsing patients.